EUVIMEDEUVIMED entdecken
Crossref

Suppression of the STAT3/MYC/MCL-1 pathway by the fixed Jianpi Huoxue Formula relieves early biochemical abnormalities in liver fibrosis

Long Huang, Cheng-Gui Wu, Teng-Fei Zhu, Qing-Lin Li, Qing-Sheng Yu, Qi Zhang, Yi Shen

World Journal of Hepatology · 27.08.2026 · 18 (8)

DOI: 10.4254/wjh.122262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Hepatology, online erschienen am 27.08.2026. Verfasst von Long Huang und 6 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Liver fibrosis (LF), a core pathological process driving chronic liver disease, has no ideal clinical intervention approaches. A fixed Jianpi Huoxue Formula (FJHF), a traditional Chinese medicine (TCM) prescription derived from the Sijunzi Decoction and Taohong Siwu Decoction, has shown clinical benefits against LF. AIM To investigate the mechanism by which FJHF attenuates LF via STAT3/MYC/MCL-1 pathway regulation. METHODS Three strategies were integrated: (1) Clinical single-cell RNA sequencing (scRNA-seq) was performed on liver tissues from three untreated cirrhosis patients and three FJHF-treated patients to characterize hepatic cell heterogeneity and FJHF-responsive gene expression; (2) A randomized controlled trial was conducted in 40 cirrhosis patients with hypersplenism (20 each in the Jianpi Huoxue Formula and control groups) to assess a hepatocellular injury indicator alanine aminotransferase (ALT), hepatic reserve function indicators [total bilirubin (TBIL) and prothrombin time], and fibrosis indicators [hyaluronic acid (HA), laminin, type III procollagen N-terminal peptide (PIIINP), and type IV collagen (CIV)]; and (3) In vitro experiments were performed in human hepatic stellate cells (HSCs) LX-2 using cell counting kit-8, transmission electron microscopy, western blotting, and quantitative real-time PCR to verify the regulatory role of FJHF in the STAT3/MYC/MCL-1 pathway. RESULTS FJHF modulated the proportion of HSC populations in a small-sample scRNA-seq cohort. According to clinical data, FJHF treatment significantly decreased ALT (P < 0.01), TBIL (P < 0.05), and the fibrosis markers HA, PIIINP, and CIV (P < 0.05) compared to the control group. In vitro , 20% FJHF-containing serum suppressed HSC activation, as indicated by reduced α-SMA, collagen I, and TIMP1 levels and elevated MMP1 levels. Notably, FJHF inhibits the STAT3/MYC/MCL-1 pathway to ameliorate LF. CONCLUSION Short-term FJHF intervention improves early biochemical abnormalities in LF by inhibiting the STAT3/MYC/MCL-1 pathway and suppressing HSC activation. This work provides a scientific basis for the application of FJHF and identifies the STAT3/MYC/MCL-1 axis as a potential target for TCM intervention in early LF metabolic abnormalities.

Zitieren

APA

Huang, L., Wu, C., Zhu, T., Li, Q., Yu, Q., Zhang, Q., & Shen, Y. (2026). Suppression of the STAT3/MYC/MCL-1 pathway by the fixed Jianpi Huoxue Formula relieves early biochemical abnormalities in liver fibrosis. World Journal of Hepatology, 18(8). https://doi.org/10.4254/wjh.122262

Vancouver

Huang L, Wu C, Zhu T, Li Q, Yu Q, Zhang Q, et al. Suppression of the STAT3/MYC/MCL-1 pathway by the fixed Jianpi Huoxue Formula relieves early biochemical abnormalities in liver fibrosis. World Journal of Hepatology. 2026;18(8). doi:10.4254/wjh.122262

BibTeX
@article{Huang2026,
  author = {Huang, Long and Wu, Cheng-Gui and Zhu, Teng-Fei and Li, Qing-Lin and Yu, Qing-Sheng and Zhang, Qi and Shen, Yi},
  title = {Suppression of the STAT3/MYC/MCL-1 pathway by the fixed Jianpi Huoxue Formula relieves early biochemical abnormalities in liver fibrosis},
  journal = {World Journal of Hepatology},
  year = {2026},
  volume = {18},
  number = {8},
  doi = {10.4254/wjh.122262}
}
Kostenlos starten →